These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18650191)

  • 1. Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
    Gibson TB; Grothey E; Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):233-9. PubMed ID: 18650191
    [No Abstract]   [Full Text] [Related]  

  • 2. [Metastatic colorectal cancer: adjournments from ESMO 2006].
    Bonetti A; Cascinu S; Falcone A; Maiello E; Zaniboni A; Aschele C
    Tumori; 2006; 92(6):1-12. PubMed ID: 17262903
    [No Abstract]   [Full Text] [Related]  

  • 3. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
    Maung K; Lee D; DeGrendele HC; Schilsky R; Chu E; Jain VK; Copur S
    Clin Colorectal Cancer; 2002 Nov; 2(3):140-5. PubMed ID: 12482329
    [No Abstract]   [Full Text] [Related]  

  • 4. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract]   [Full Text] [Related]  

  • 5. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
    Booth C
    J Clin Oncol; 2008 Oct; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
    [No Abstract]   [Full Text] [Related]  

  • 6. First-line treatment of advanced colorectal cancer.
    Hewish M; Cunningham D
    Lancet; 2011 Jun; 377(9783):2060-2. PubMed ID: 21641637
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line therapeutic strategies in metastatic colorectal cancer.
    Davies JM; Goldberg RM
    Oncology (Williston Park); 2008 Nov; 22(13):1470-9. PubMed ID: 19133603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L; Nagykálnai T
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Mayer RJ
    J Clin Oncol; 2007 Sep; 25(27):4165-7. PubMed ID: 17709796
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
    Modest DP; Brodowicz T; Stintzing S; Jung A; Neumann J; Laubender RP; Ocvirk J; Kurteva G; Papai Z; Knittelfelder R; Kirchner T; Heinemann V; Zielinski CC
    Oncology; 2012; 83(5):241-7. PubMed ID: 22948721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Loupakis F; Di Maio M; Falcone A
    N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
    [No Abstract]   [Full Text] [Related]  

  • 13. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
    Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Pohlmann PR; Mernaugh RL; Goff LW
    N Engl J Med; 2009 May; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Copur MS; Norvell M; Obermiller A
    N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445033
    [No Abstract]   [Full Text] [Related]  

  • 16. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

  • 17. Current role of bevacizumab in colorectal cancer.
    Saltz L
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
    [No Abstract]   [Full Text] [Related]  

  • 18. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
    Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
    Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
    Tol J; Koopman M; Rodenburg CJ; Cats A; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; Mol L; Antonini NF; Punt CJ
    Ann Oncol; 2008 Apr; 19(4):734-8. PubMed ID: 18272912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.